New Trial Tests Oral Drug Plus Nanoliposomal Irinotecan for Hard-to-Treat Bile Duct Cancer

Advanced biliary tract cancer is one of the most unforgiving diagnoses in oncology. These tumors, which arise from the cells lining the bile ducts and gallbladder, are often discovered late, spread quietly through the liver and abdomen, and respond poorly to most therapies. Once the disease progresses after standard first-line chemotherapy with gemcitabine-based regimens, patients and their doctors are left with remarkably few options, and the outcomes of those options remain modest at best. It is precisely this therapeutic gap that a new investigator-initiated study, known as TRITICC-2, is designed to address. The trial, described in a study protocol published in BMC Cancer, will test whether combining two drugs with very different mechanisms of action can meaningfully extend the time patients live without their cancer worsening.

The regimen under investigation pairs trifluridine/tipiracil, an oral drug commonly abbreviated as FTD/TPI, with nanoliposomal irinotecan, a nanoparticle-encapsulated formulation of the classic chemotherapy agent irinotecan. Both components have already demonstrated clinical activity in gastrointestinal malignancies, but the logic of the combination goes deeper than convenience. Trifluridine is a thymidine analog that incorporates itself into replicating DNA and disrupts synthesis, while tipiracil inhibits the enzyme that would otherwise rapidly degrade trifluridine in the liver, thereby sustaining effective drug levels after oral administration. Nanoliposomal irinotecan, meanwhile, wraps the topoisomerase I inhibitor irinotecan inside a lipid bilayer roughly one hundred nanometers across, prolonging its circulation in the bloodstream and altering its distribution toward tumor tissue. The researchers hypothesize that these two mechanisms may produce synergistic antitumor effects when deployed together.

TRITICC-2 is structured as a prospective, open-label, multicenter, single-arm phase II trial conducted at academic centers across Germany. The single-arm design means that all enrolled patients receive the experimental combination, and results will be compared against historical benchmarks rather than a concurrent control group. This approach is common for early-phase studies in rare cancers, where the small patient population makes randomized designs difficult and slow. A total of 38 patients are planned for enrollment, all of whom must have histologically confirmed, unresectable or metastatic biliary tract cancer and documented disease progression on gemcitabine-based first-line therapy. Recruitment was initiated in late 2025 and is ongoing, with efficacy, safety, and translational analyses still pending.

The treatment schedule reflects a careful balancing of efficacy against toxicity. Patients receive oral trifluridine/tipiracil on days one through five of each cycle, combined with an intravenous infusion of nanoliposomal irinotecan on day one. Cycles repeat every fourteen days, and treatment continues until disease progression, unacceptable toxicity, or withdrawal of consent. This two-week rhythm allows the oral component to hit the tumor repeatedly during each cycle while the long-circulating liposomal formulation maintains a sustained presence. The primary endpoint of the trial is progression-free survival, the length of time patients live without their disease advancing, which is a clinically meaningful measure in a setting where cure is not the realistic goal.

Secondary endpoints broaden the picture considerably. The investigators will track overall survival, the objective response rate as measured by standard imaging criteria, and the safety profile of the combination, graded according to the National Cancer Institute’s common toxicity criteria. Importantly, the trial also incorporates health-related quality of life assessments using validated instruments, including the EORTC QLQ-C30 questionnaire and the EQ-5D-5L. This attention to how patients actually feel and function during treatment matters enormously in a palliative setting, where a regimen that adds weeks of survival at the cost of debilitating side effects may offer little real benefit. The open-label design means patients and physicians know which treatment is being given, which is typical for trials of this size and phase but does introduce potential bias in subjective endpoints.

Beyond the clinical measurements, TRITICC-2 includes an optional translational research program that could prove scientifically valuable in its own right. Participants may undergo serial liquid biopsies, meaning repeated analyses of cell-free DNA and other biomarkers circulating in their blood, allowing researchers to track the molecular evolution of their tumors over time without repeated invasive tissue biopsies. By correlating these biomarker dynamics with treatment response and resistance, the investigators hope to identify markers associated with benefit from the combination. In an era when precision oncology increasingly depends on understanding which molecular features predict drug sensitivity, such prospective translational data from a rare cancer are genuinely scarce and correspondingly precious.

The trial’s governance structure follows the rigorous standards expected of modern European clinical research. The study is registered under the European Union Clinical Trials Regulation with the number EUCT 2024-517330-18-00, and its protocol is publicly accessible through the CTIS portal. Heinrich-Heine-University Düsseldorf serves as the sponsor, while the study is fully funded by Les Laboratoires Servier as an investigator-initiated trial, meaning the scientific questions and study design are driven by the academic investigators rather than the company. An independent data monitoring committee, composed of two gastroenterology specialists and one biostatistician, all of whom have declared no competing interests, reviews safety data twice a year and can request additional reviews at any time, with authority to recommend continuation, modification, or termination of the trial.

Quality assurance measures embedded in the protocol underscore the seriousness of the effort. A risk-based monitoring strategy ensures that every participating site receives at least one on-site visit per year, with visits concentrated on the data and processes most critical to study integrity. These on-site activities are complemented by centralized monitoring performed by data managers and biostatisticians. Written informed consent is required from all participants, and the trial operates under Good Clinical Practice standards and the German Medicine Act. Notably, no interim efficacy analyses are planned, which avoids the statistical complications of repeatedly testing the data, and the investigators have committed to publishing results regardless of whether the outcome is positive or negative, a pledge that remains disappointingly rare in clinical research.

For patients with advanced biliary tract cancer, the stakes of this trial could hardly be higher. The disease encompasses cholangiocarcinoma in its intrahepatic, perihilar, and distal forms as well as gallbladder carcinoma, and together these malignancies account for a substantial burden of cancer mortality worldwide, with incidence rising in many countries. Second-line treatment options after gemcitabine failure have historically delivered limited benefit, and while molecularly targeted therapies have emerged for the small subset of patients with actionable mutations such as IDH1 or FGFR2 alterations, the majority of patients still lack personalized options. A well-tolerated, orally anchored combination regimen could, if successful, offer a practical new standard that does not require specialized molecular testing infrastructure.

The TRITICC-2 study also illustrates a broader trend in oncology drug development: the intelligent repurposing of established agents into rational combinations for underserved tumor types. Neither trifluridine/tipiracil nor nanoliposomal irinotecan is a new molecule, but their pairing applies mechanistic reasoning and formulation science to a population with high unmet medical need. With enrollment underway and results still to come, the trial will not deliver answers immediately. Yet its design, transparency, and translational ambitions make it a study worth watching, both for the patients it may ultimately help and for the biomarker insights it may generate about how biliary tract cancers evolve and evade treatment.

Subject of Research: A phase II trial of trifluridine/tipiracil plus nanoliposomal irinotecan as second-line therapy for advanced biliary tract cancer

Article Title: Study protocol: a phase II study of trifluridine/tipiracil plus liposomal irinotecan as second-line therapy in advanced biliary tract cancer (TRITICC 2)

Article References: Kehmann, L., Götze, T., Gonzalez-Carmona, M., Foerster, F., Berres, M., Mohr, R., Koch, A., Das, S., Drusenheimer, N., Kebede, T., Joerdens, M., Luedde, T., & Roderburg, C. (2026). Study protocol: a phase II study of trifluridine/tipiracil plus liposomal irinotecan as second-line therapy in advanced biliary tract cancer (TRITICC 2). BMC Cancer. https://doi.org/10.1186/s12885-026-17089-6

Image Credits: AI Generated

DOI: 10.1186/s12885-026-17089-6

Keywords: biliary tract cancer, cholangiocarcinoma, trifluridine/tipiracil, nanoliposomal irinotecan, phase II trial, second-line therapy, progression-free survival, liquid biopsy, clinical trial, oncology, chemotherapy, translational research